Upadacitinib in moderate to severe crohns disease who have failed or are intolerant to conventional therapy or biologics therapy: a real world experience from a single tertiary centre

In this study we will acquire the real-world data on the safety and efficacy of Upadacitinib in the management of Crohn’s disease at a single tertiary care center at IPGMER & SSKM Hospital. We will evaluate the clinical response of CD patients to Upadacitinib who are refractory/intolerant to conventional or biological therapy in a real-world setting. We will also evaluate the safety and tolerability of Upadacitinib in CD patients. We will also identify the baseline predictors for therapeutic response to Upadacitinib. Appropriate statistical analysis shall be applied. After applying proper inclusion and exclusion criteria, we shall enroll subjects in our study. Duration of enrollment of  study will be till  May month of 2027.